Abstracts tagged "abatacept and remission"

Abstract Number: 1465 • 2017 ACR/ARHP Annual Meeting
Cost per Response for Abatacept Versus Adalimumab in Patients with Seropositive, Erosive, Early Rheumatoid Arthritis in the US, Germany, Spain and Canada
J Foo¹, JM Rodriguez Heredia², C Polanco Sánchez³, M Mtibaa⁴, KH Herrmann⁵, E Alemao⁶, R Postema⁷ and C Baerwald⁸, ¹Mapi Group, Houten, Netherlands, ²Hospital Universitario de Getafe, Madrid, Spain, ³Bristol-Myers Squibb, Madrid, Spain, ⁴Bristol-Myers Squibb, Montréal, QC, Canada, ⁵Bristol-Myers Squibb, Munich, Germany, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷Bristol-Myers Squibb, Uxbridge, United Kingdom, ⁸University Hospital, Department of Internal Medicine, Rheumatology Unit, Leipzig, Germany
Background/Purpose: RA is a chronic, inflammatory disorder leading to disability and reduced quality of life. Effective treatment with biologic DMARDs poses a significant economic burden.…
Abstract Number: 1644 • 2015 ACR/ARHP Annual Meeting
Routine Assessment of Patient Index Data 3 (RAPID3)-Defined Remission Is As Stringent As ACR/EULAR Boolean-Defined Remission in a Clinical Trial of Patients with Early Rheumatoid Arthritis Treated with Abatacept
Yusuf Yazici¹, KK Gandhi², E Alemao² and Daniel E. Furst³, ¹NYU Hospital for Joint Diseases, New York, NY, ²Bristol-Myers Squibb, Princeton, NJ, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Routine Assessment of Patient Index Data 3 (RAPID3) comprises the three patient-reported ACR RA Core Data Set measures: function (HAQ-DI), pain and patient global…
Abstract Number: 2485 • 2014 ACR/ARHP Annual Meeting
Predictors of Drug-Free Remission Following Treatment with Abatacept (in Combination with Methotrexate or as Monotherapy) in Early Rheumatoid Arthritis
P Emery¹, Gerd Burmester², Vivian P. Bykerk³, B Combe⁴, Daniel E. Furst⁵, E Barre⁶, C S Karyekar⁷, D Wong⁷ and T W J Huizinga⁸, ¹University of Leeds, Leeds, United Kingdom, ²Charité – University Medicine Berlin, Berlin, Germany, ³Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁴Monpellier University Hospital, Montpellier, France, ⁵University of California at Los Angeles, Los Angeles, CA, ⁶Bristol-Myers Squibb, Braine-L’Alleud, Belgium, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the Phase IIIb, randomized, double-blind, active-controlled AVERT study, abatacept (ABA) + MTX and ABA monotherapy induced protocol-defined DAS remission (DAS28 [CRP]
Abstract Number: 2356 • 2013 ACR/ARHP Annual Meeting
Soluble Interleukin-2 Receptor Levels and The CD4/CD8 Ratio As Predictors Of The Efficacy Of Abatacept In Biologics-naïve Rheumatoid Arthritis Patients
Hajime Sano¹, Masahiro Sekiguchi¹, Masayasu Kitano¹, Naoto Azuma¹, Shinichiro Tsunoda¹, Kiyoshi Matsui¹ and Tsuyoshi Iwasaki², ¹Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya-city, Japan, ²Department of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan
Background/Purpose: Abatacept (ABT) is a recombinant fusion protein consisting of the extracellular domain of human CTLA-4, binding to CD80/86 on antigen presenting cells and thereby…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].